Latest Clinical Trials
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) National Cancer Institute (NCI) NA SUSPENDED
(Sep 21, 2026)
PHASE1, PHASE2 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy ETOP IBCSG Partners Foundation NA TERMINATED
(Sep 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Hoffmann-La Roche NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery ECOG-ACRIN Cancer Research Group NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Children's Oncology Group NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Carboplatin or Olaparib for BRcA Deficient Prostate Cancer VA Office of Research and Development NA RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Masonic Cancer Center, University of Minnesota NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Memorial Sloan Kettering Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE2 EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib Genprex, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies AstraZeneca NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Genmab NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer Hoffmann-La Roche NA COMPLETED
(Sep 1, 2026)
PHASE3 Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma National Cancer Institute (NCI) NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Children's Oncology Group NA RECRUITING
(Sep 1, 2026)
PHASE2 Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer Muhammad Furqan NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy M.D. Anderson Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE2 Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) M.D. Anderson Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE2 Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. Zhigang Li NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer AstraZeneca NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE1 A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer Hoffmann-La Roche NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Gilead Sciences NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer People's Hospital of Quzhou NA COMPLETED
(Sep 1, 2026)
PHASE2 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration ORIC Pharmaceuticals NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Amgen NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC University of Maryland, Baltimore NA SUSPENDED
(Sep 1, 2026)
PHASE1 A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation D3 Bio (Wuxi) Co., Ltd NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 De-escalation Study for Stage IIa/IIb < 3 cm Seminoma Centre Leon Berard NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma Hoffmann-La Roche NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma St. Jude Children's Research Hospital NA RECRUITING
(Sep 1, 2026)
PHASE2 Study of Trilaciclib and Lurbinectidin UNC Lineberger Comprehensive Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE2 Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients Genprex, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy Hackensack Meridian Health NA TERMINATED
(Sep 1, 2026)
PHASE2 Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck ECOG-ACRIN Cancer Research Group NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Imunon NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation Hoffmann-La Roche NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer Guangzhou Gloria Biosciences Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE3 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) Amgen NA RECRUITING
(Sep 1, 2026)
PHASE3 Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer National Cancer Institute (NCI) NA RECRUITING
(Sep 1, 2026)
PHASE2 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Neonc Technologies, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Memorial Sloan Kettering Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE2 DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer Boehringer Ingelheim NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment Boehringer Ingelheim NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC H. Lee Moffitt Cancer Center and Research Institute NA COMPLETED
(Sep 1, 2026)
PHASE1 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3 Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy BioNTech SE NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer Jin Ying NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1 A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer Memorial Sloan Kettering Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE3 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features AstraZeneca NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). Bristol-Myers Squibb NA RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) mAbxience Research S.L. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) AstraZeneca NA RECRUITING
(Sep 1, 2026)
PHASE3 Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 Gilead Sciences NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche NA RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE2 Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer Daiichi Sankyo NA RECRUITING
(Sep 1, 2026)
PHASE3 Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer Imunon NA RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3 A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors Wigen Biomedicine Technology (Shanghai) Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer AstraZeneca NA RECRUITING
(Sep 1, 2026)
PHASE3 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Amgen NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma Fox Chase Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE2 Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine NA RECRUITING
(Sep 1, 2026)
PHASE2 JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma Shanghai Junshi Bioscience Co., Ltd. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Hospital das Clínicas de Ribeirão Preto NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE2 ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer BioNTech SE NA RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3 Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma National Cancer Institute (NCI) NA RECRUITING
(Sep 1, 2026)
PHASE2 Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Washington University School of Medicine NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. Eikon Therapeutics NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy Boehringer Ingelheim NA RECRUITING
(Sep 1, 2026)
PHASE3 Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC Ji Dongmei NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer Memorial Sloan Kettering Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE1 DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy Boehringer Ingelheim NA RECRUITING
(Sep 1, 2026)
PHASE3 A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. Hangzhou DAC Biotechnology Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer Jiangmen Central Hospital NA RECRUITING
(Sep 1, 2026)
PHASE2 BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) SystImmune Inc. NA RECRUITING
(Sep 1, 2026)
PHASE3 Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. Fudan University NA RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) GlaxoSmithKline NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery West China Hospital NA RECRUITING
(Sep 1, 2026)
PHASE1 A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) Merck Sharp & Dohme LLC NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin University of Colorado, Denver NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Hansoh BioMedical R&D Company NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer Chinese PLA General Hospital NA RECRUITING
(Sep 1, 2026)
PHASE3 Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma caohaotian NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations RemeGen Co., Ltd. NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer University College, London NA RECRUITING
(Sep 1, 2026)
PHASE3 A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation Shanghai Jeyou Pharmaceutical Co., Ltd. NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors CSPC Megalith Biopharmaceutical Co.,Ltd. NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Vanderbilt-Ingram Cancer Center NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer City of Hope Medical Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer AstraZeneca NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Julie Krystal NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors St. Jude Children's Research Hospital NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma Washington University School of Medicine NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Alicia Lenzen NA COMPLETED
(Aug 1, 2026)
PHASE3 Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL City of Hope Medical Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Dana-Farber Cancer Institute NA COMPLETED
(Aug 1, 2026)
PHASE2 Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma City of Hope Medical Center NA COMPLETED
(Aug 1, 2026)
PHASE1 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency University of Washington NA TERMINATED
(Aug 1, 2026)
PHASE2 A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors MedImmune LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) AstraZeneca NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer CStone Pharmaceuticals NA COMPLETED
(Aug 1, 2026)
PHASE3 Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 'ADVANCE' (A Pilot Trial) Dana-Farber Cancer Institute NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors AbbVie NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC ETOP IBCSG Partners Foundation NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol NRG Oncology NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) AstraZeneca NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) Merck Sharp & Dohme LLC NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) Merck Sharp & Dohme LLC NA TERMINATED
(Aug 1, 2026)
PHASE2 Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy Wake Forest University Health Sciences NA RECRUITING
(Aug 1, 2026)
PHASE2 Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer AstraZeneca NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer AstraZeneca NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery NRG Oncology NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). Incyte Corporation NA COMPLETED
(Aug 1, 2026)
PHASE3 A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer Latin American Cooperative Oncology Group NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma City of Hope Medical Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Wake Forest University Health Sciences NA RECRUITING
(Aug 1, 2026)
PHASE2 Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib Beijing Cancer Prevention & Treatment Society NA COMPLETED
(Aug 1, 2026)
PHASE2 Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study Jonathan Schoenfeld, MD, MPH NA RECRUITING
(Aug 1, 2026)
PHASE2 Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers Latin American Cooperative Oncology Group NA COMPLETED
(Aug 1, 2026)
PHASE2 A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma St. Petersburg State Pavlov Medical University NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 AB122 Platform Study Taiho Pharmaceutical Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE1 Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors Astellas Pharma Global Development, Inc. NA TERMINATED
(Aug 1, 2026)
PHASE1 A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab Novartis Pharmaceuticals NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy University Hospital, Strasbourg, France NA RECRUITING
(Aug 1, 2026)
PHASE2 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Merck Sharp & Dohme LLC NA TERMINATED
(Aug 1, 2026)
PHASE3 HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Daiichi Sankyo NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE2 An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer Montefiore Medical Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer Memorial Sloan Kettering Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE2 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Genmab NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NRG Oncology NA RECRUITING
(Aug 1, 2026)
PHASE3 Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors AstraZeneca NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM CarThera NA RECRUITING
(Aug 1, 2026)
PHASE3 Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer Wake Forest University Health Sciences NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer BeiGene NA COMPLETED
(Aug 1, 2026)
PHASE1 Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE3 A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) AstraZeneca NA RECRUITING
(Aug 1, 2026)
PHASE3 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations AstraZeneca NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK Swiss Cancer Institute NA RECRUITING
(Aug 1, 2026)
PHASE2 Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors MediLink Therapeutics (Suzhou) Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE1 A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) GlaxoSmithKline NA TERMINATED
(Aug 1, 2026)
PHASE1, PHASE2 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation Allist Pharmaceuticals, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3 Volrustomig Priming Regimens Exploratory Phase II Platform Study AstraZeneca NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery ARCAGY/ GINECO GROUP NA RECRUITING
(Aug 1, 2026)
PHASE3 Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations BeBetter Med Inc NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE3 N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma Memorial Sloan Kettering Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) Hoffmann-La Roche NA COMPLETED
(Aug 1, 2026)
PHASE3 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer Alliance for Clinical Trials in Oncology NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) Johnson & Johnson Enterprise Innovation Inc. NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer BeBetter Med Inc NA COMPLETED
(Aug 1, 2026)
PHASE2 A Study of GC101 TIL in Advanced Melanoma Shanghai Juncell Therapeutics NA RECRUITING
(Aug 1, 2026)
PHASE2 Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer BioNTech SE NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) Merck Sharp & Dohme LLC NA RECRUITING
(Aug 1, 2026)
PHASE2 Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer Peking University Cancer Hospital & Institute NA RECRUITING
(Aug 1, 2026)
PHASE2 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] Nanjing Leads Biolabs Co.,Ltd NA RECRUITING
(Aug 1, 2026)
PHASE2 Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) Merck Sharp & Dohme LLC NA RECRUITING
(Aug 1, 2026)
PHASE2 Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BeBetter Med Inc NA RECRUITING
(Aug 1, 2026)
PHASE3 A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) Latin American Cooperative Oncology Group NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC） Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA ENROLLING BY INVITATION
(Aug 1, 2026)
PHASE2, PHASE3 Toripalimab With Chemotherapy for Sinus Cancer Dana-Farber Cancer Institute NA RECRUITING
(Aug 1, 2026)
PHASE2 Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation Allist Pharmaceuticals, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases Allist Pharmaceuticals, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3 Head and Neck Cancer Study Project in the Geriatric Population Brown University NA RECRUITING
(Aug 1, 2026)
PHASE3 Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer Cedars-Sinai Medical Center NA RECRUITING
(Aug 1, 2026)
PHASE2 Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer PrECOG, LLC. NA RECRUITING
(Aug 1, 2026)
PHASE2 Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer SWOG Cancer Research Network NA ENROLLING BY INVITATION
(Aug 1, 2026)
PHASE2 DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) Dizal Pharmaceuticals NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC CatalYm GmbH NA RECRUITING
(Aug 1, 2026)
PHASE2 A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer Jazz Pharmaceuticals NA RECRUITING
(Aug 1, 2026)
PHASE2 ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy Jiangsu Aosaikang Pharmaceutical Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE3 A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) BioNTech SE NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection Taiho Oncology, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Daiichi Sankyo NA RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer Takeda NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma Johnson & Johnson Enterprise Innovation Inc. NA RECRUITING
(Aug 1, 2026)
PHASE1 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) Merck Sharp & Dohme LLC NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors Astellas Pharma Global Development, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease Intergroupe Francophone de Cancerologie Thoracique NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin NRG Oncology NA RECRUITING
(Aug 1, 2026)
PHASE3 Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab Boehringer Ingelheim NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer BeBetter Med Inc NA RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung Technische Universität Dresden NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Genmab NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE2 A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE2 Thermotherapy for Head and Neck Cancer Patients Erasmus Medical Center NA RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer CSPC Megalith Biopharmaceutical Co.,Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE2 A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC Nanjing Leads Biolabs Co.,Ltd NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma National Cancer Institute (NCI) NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer Tubulis GmbH NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) Sichuan Baili Pharmaceutical Co., Ltd. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) Sichuan Baili Pharmaceutical Co., Ltd. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer MediLink Therapeutics (Suzhou) Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE3 Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC Yanjie Zhang, MD NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma Tang-Du Hospital NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC Jiangsu Hansoh Pharmaceutical Co., Ltd. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants AbbVie NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) Shandong New Time Pharmaceutical Co., LTD NA RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer Memorial Sloan Kettering Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE2 Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial Sichuan Cancer Hospital and Research Institute NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Sun Yat-sen University NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC Revolution Medicines, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3 Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer The Affiliated Hospital of Putian University NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma Second Affiliated Hospital, Zhejiang University, School of Medicine NA RECRUITING
(Aug 1, 2026)
PHASE2 Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC M.D. Anderson Cancer Center NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC University of Texas Southwestern Medical Center NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer Masaryk Memorial Cancer Institute NA COMPLETED
(Aug 1, 2026)
PHASE2 A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Taizhou Mabtech Pharmaceutical Co.,Ltd NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer Qilu Pharmaceutical Co., Ltd. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC Hubei Cancer Hospital NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Sixth Affiliated Hospital, Sun Yat-sen University NA RECRUITING
(Aug 1, 2026)
PHASE2 Perioperative Adebrelimab for Locally Advanced Cervical Cancer Anhui Provincial Hospital NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy Fudan University NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma Jennerex Biotherapeutics NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma University of Washington NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 MPDL3280A With Chemoradiation for Lung Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Wake Forest University Health Sciences NA COMPLETED
(Jul 1, 2026)
PHASE2 Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer University of Michigan Rogel Cancer Center NA COMPLETED
(Jul 1, 2026)
PHASE2 A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer Hoffmann-La Roche NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Seagen, a wholly owned subsidiary of Pfizer NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer National Cancer Institute (NCI) NA RECRUITING
(Jul 1, 2026)
PHASE2 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Merck Sharp & Dohme LLC NA COMPLETED
(Jul 1, 2026)
PHASE3 APG-115 in Salivary Gland Cancer Trial University of Michigan Rogel Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer Seagen, a wholly owned subsidiary of Pfizer NA TERMINATED
(Jul 1, 2026)
PHASE1, PHASE2 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) Merck Sharp & Dohme LLC NA COMPLETED
(Jul 1, 2026)
PHASE3 Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Washington University School of Medicine NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Inhibrx Biosciences, Inc NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) National Cancer Institute (NCI) NA RECRUITING
(Jul 1, 2026)
PHASE3 A Study of Sigvotatug Vedotin in Advanced Solid Tumors Seagen, a wholly owned subsidiary of Pfizer NA RECRUITING
(Jul 1, 2026)
PHASE1 Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy Wake Forest University Health Sciences NA COMPLETED
(Jul 1, 2026)
PHASE2 Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer Instituto Oncológico Dr Rosell NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach University of Maryland, Baltimore NA TERMINATED
(Jul 1, 2026)
PHASE2 A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma Shanghai Junshi Bioscience Co., Ltd. NA WITHDRAWN
(Jul 1, 2026)
PHASE3 Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) Stanford University NA SUSPENDED
(Jul 1, 2026)
PHASE2 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer University of Alabama at Birmingham NA RECRUITING
(Jul 1, 2026)
PHASE2 Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Memorial Sloan Kettering Cancer Center NA RECRUITING
(Jul 1, 2026)
PHASE1 Study of AZD2811 + Durvalumab in ES-SCLC AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers UNICANCER NA RECRUITING
(Jul 1, 2026)
PHASE3 A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) Fundación GECP NA COMPLETED
(Jul 1, 2026)
PHASE2 First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Wake Forest University Health Sciences NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer Memorial Sloan Kettering Cancer Center NA COMPLETED
(Jul 1, 2026)
PHASE2 Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) Merck Sharp & Dohme LLC NA COMPLETED
(Jul 1, 2026)
PHASE2 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Glenn J. Hanna NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma National Cancer Institute (NCI) NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung National Cancer Institute (NCI) NA SUSPENDED
(Jul 1, 2026)
PHASE2, PHASE3 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer BioNTech SE NA RECRUITING
(Jul 1, 2026)
PHASE1 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma National Cancer Institute (NCI) NA RECRUITING
(Jul 1, 2026)
PHASE3 Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations Juntendo University NA COMPLETED
(Jul 1, 2026)
PHASE2 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) Merck Sharp & Dohme LLC NA COMPLETED
(Jul 1, 2026)
PHASE3 A Study of ASP3082 in Adults With Advanced Solid Tumors Astellas Pharma Inc NA RECRUITING
(Jul 1, 2026)
PHASE1 Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer Heath Skinner NA RECRUITING
(Jul 1, 2026)
PHASE2 A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy North Eastern German Society of Gynaecological Oncology NA RECRUITING
(Jul 1, 2026)
PHASE2 A Study of ASP1002 in Adults for Treatment of Solid Tumors Astellas Pharma Global Development, Inc. NA RECRUITING
(Jul 1, 2026)
PHASE1 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer Regeneron Pharmaceuticals NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma David Bond, MD NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Seagen, a wholly owned subsidiary of Pfizer NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. Centre Georges Francois Leclerc NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment Guangdong Association of Clinical Trials NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) Taiho Oncology, Inc. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study University of Washington NA RECRUITING
(Jul 1, 2026)
PHASE2 Atezolizumab in Large Cell Neuroendocrine Carcinoma Oncology Center of Biochemical Education And Research NA COMPLETED
(Jul 1, 2026)
PHASE1 NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) Women's Cancer Study Group GmbH NA RECRUITING
(Jul 1, 2026)
PHASE3 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer Yonsei University NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma Hyogo Medical University NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer Samsung Bioepis Co., Ltd. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) Sichuan Baili Pharmaceutical Co., Ltd. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Phase III Study of AK112 for NSCLC Patients Summit Therapeutics NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer Dustin Deming NA RECRUITING
(Jul 1, 2026)
PHASE2 Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer MedSIR NA COMPLETED
(Jul 1, 2026)
PHASE2 A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer University of Miami NA RECRUITING
(Jul 1, 2026)
PHASE2 PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer Medical College of Wisconsin NA RECRUITING
(Jul 1, 2026)
PHASE2 JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC Shanghai Junshi Bioscience Co., Ltd. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC Shanghai Junshi Bioscience Co., Ltd. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Platform Study in Non-Small Cell Lung Cancer (NSCLC) AstraZeneca NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer Daiichi Sankyo NA RECRUITING
(Jul 1, 2026)
PHASE3 A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer University of Washington NA RECRUITING
(Jul 1, 2026)
PHASE2 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer IDEAYA Biosciences NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer TORL Biotherapeutics, LLC NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Revolution Medicines, Inc. NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC Massachusetts General Hospital NA RECRUITING
(Jul 1, 2026)
PHASE2 RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) RemeGen Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE3 A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) Sichuan Baili Pharmaceutical Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE3 Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy Fudan University NA RECRUITING
(Jul 1, 2026)
PHASE3 A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy Henan Cancer Hospital NA RECRUITING
(Jul 1, 2026)
PHASE2 Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine NA RECRUITING
(Jul 1, 2026)
PHASE2 Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer ARCAGY/ GINECO GROUP NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) Sichuan Baili Pharmaceutical Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer Akeso NA RECRUITING
(Jul 1, 2026)
PHASE2 Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients Guangzhou University of Traditional Chinese Medicine NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden AIO-Studien-gGmbH NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Medical University of South Carolina NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial The First Affiliated Hospital with Nanjing Medical University NA RECRUITING
(Jul 1, 2026)
PHASE2 Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer? Odense University Hospital NA RECRUITING
(Jul 1, 2026)
PHASE1 Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC Tianjin Medical University Cancer Institute and Hospital NA RECRUITING
(Jul 1, 2026)
PHASE2 Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma West China Hospital NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Elemene Liposomes in Endometrial Cancer Women's Hospital School Of Medicine Zhejiang University NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study of DS-3939a in Participants With Solid Tumors Daiichi Sankyo NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC University of Kansas Medical Center NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma AbbVie NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer M.D. Anderson Cancer Center NA TERMINATED
(Jun 1, 2026)
PHASE2 Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss Sound Pharmaceuticals, Incorporated NA WITHDRAWN
(Jun 1, 2026)
PHASE2 Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma St. Jude Children's Research Hospital NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Radiation Therapy Oncology Group NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer NRG Oncology NA COMPLETED
(Jun 1, 2026)
PHASE2 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Merck Sharp & Dohme LLC NA COMPLETED
(Jun 1, 2026)
PHASE3 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Alliance for Clinical Trials in Oncology NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer M.D. Anderson Cancer Center NA COMPLETED
(Jun 1, 2026)
PHASE2 Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer AstraZeneca NA COMPLETED
(Jun 1, 2026)
PHASE3 Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects Novartis Pharmaceuticals NA TERMINATED
(Jun 1, 2026)
PHASE3 Comparing Palliative Radiotherapy With or Without Carboplatin Institut Cancerologie de l'Ouest NA TERMINATED
(Jun 1, 2026)
PHASE3 Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma NRG Oncology NA TERMINATED
(Jun 1, 2026)
PHASE3 Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC University of Utah NA TERMINATED
(Jun 1, 2026)
PHASE2 Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer Washington University School of Medicine NA TERMINATED
(Jun 1, 2026)
PHASE1, PHASE2 Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance Abramson Cancer Center at Penn Medicine NA RECRUITING
(Jun 1, 2026)
PHASE2 Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) GWT-TUD GmbH NA COMPLETED
(Jun 1, 2026)
PHASE3 Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Marcelo Bonomi NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer Li Zhang, MD NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers Synthekine NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer Ohio State University Comprehensive Cancer Center NA RECRUITING
(Jun 1, 2026)
PHASE1 Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA RECRUITING
(Jun 1, 2026)
PHASE2 A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies Ellipses Pharma NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Daiichi Sankyo NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer West German Study Group NA RECRUITING
(Jun 1, 2026)
PHASE2 Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC Dana-Farber Cancer Institute NA RECRUITING
(Jun 1, 2026)
PHASE2 Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma University Hospital, Antwerp NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer Hoffmann-La Roche NA COMPLETED
(Jun 1, 2026)
PHASE2 CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer Lan Coffman NA RECRUITING
(Jun 1, 2026)
PHASE1 Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro University of Alabama at Birmingham NA RECRUITING
(Jun 1, 2026)
PHASE2 Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer University Health Network, Toronto NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) Children's National Research Institute NA RECRUITING
(Jun 1, 2026)
PHASE1 DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC University of Alabama at Birmingham NA RECRUITING
(Jun 1, 2026)
PHASE2 Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy BioNTech SE NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC Guangzhou Institute of Respiratory Disease NA RECRUITING
(Jun 1, 2026)
PHASE2 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma Immatics US, Inc. NA RECRUITING
(Jun 1, 2026)
PHASE3 Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab Regina Elena Cancer Institute NA RECRUITING
(Jun 1, 2026)
PHASE2 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations Alterome Therapeutics, Inc. NA RECRUITING
(Jun 1, 2026)
PHASE1 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma University of California, Davis NA RECRUITING
(Jun 1, 2026)
PHASE2 A Study of LY4175408 in Participants With Advanced Cancer Eli Lilly and Company NA RECRUITING
(Jun 1, 2026)
PHASE1 Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA RECRUITING
(Jun 1, 2026)
PHASE2 A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy Shanghai Chest Hospital NA RECRUITING
(Jun 1, 2026)
PHASE2 Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer National Cancer Institute (NCI) NA RECRUITING
(Jun 1, 2026)
PHASE2 Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets European Organisation for Research and Treatment of Cancer - EORTC NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) NA RECRUITING
(Jun 1, 2026)
PHASE2 SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer Sinocelltech Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA RECRUITING
(Jun 1, 2026)
PHASE2 SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer Shanghai Chest Hospital NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer Fudan University NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma Aveta Biomics, Inc. NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Harbin Medical University NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Children's Oncology Group NA COMPLETED
(May 1, 2026)
PHASE3 Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer National Cancer Institute (NCI) NA COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU National Cancer Institute (NCI) NA TERMINATED
(May 1, 2026)
PHASE3 Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Alliance for Clinical Trials in Oncology NA COMPLETED
(May 1, 2026)
PHASE3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer National Cancer Institute (NCI) NA COMPLETED
(May 1, 2026)
PHASE3 Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Northwell Health NA SUSPENDED
(May 1, 2026)
PHASE1, PHASE2 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer NRG Oncology NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer Genelux Corporation NA COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Paediatric Hepatic International Tumour Trial University of Birmingham NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Regeneron Pharmaceuticals NA COMPLETED
(May 1, 2026)
PHASE3 Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) Imunon NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Iovance Biotherapeutics, Inc. NA TERMINATED
(May 1, 2026)
PHASE2 Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway Centre Francois Baclesse NA COMPLETED
(May 1, 2026)
PHASE2 Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC Yonsei University NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Inhibrx Biosciences, Inc NA RECRUITING
(May 1, 2026)
PHASE1 Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC Fox Chase Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma National Cancer Institute (NCI) NA COMPLETED
(May 1, 2026)
PHASE2 Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC AstraZeneca NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer University of Oklahoma NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Centre Francois Baclesse NA COMPLETED
(May 1, 2026)
PHASE2 A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma National Cancer Institute (NCI) NA RECRUITING
(May 1, 2026)
PHASE3 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer Incyte Corporation NA COMPLETED
(May 1, 2026)
PHASE3 Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer Astellas Pharma Global Development, Inc. NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer AGO Research GmbH NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer University of Washington NA RECRUITING
(May 1, 2026)
PHASE2 Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer Brigham and Women's Hospital NA ENROLLING BY INVITATION
(May 1, 2026)
PHASE1 Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) Daiichi Sankyo NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche NA COMPLETED
(May 1, 2026)
PHASE2, PHASE3 A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Bristol-Myers Squibb NA COMPLETED
(May 1, 2026)
PHASE2 Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Brigham and Women's Hospital NA RECRUITING
(May 1, 2026)
PHASE1 A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Bristol-Myers Squibb NA COMPLETED
(May 1, 2026)
PHASE2 Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC Guangdong Association of Clinical Trials NA COMPLETED
(May 1, 2026)
PHASE3 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer Hospices Civils de Lyon NA RECRUITING
(May 1, 2026)
PHASE1 Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer City of Hope Medical Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery Weill Medical College of Cornell University NA TERMINATED
(May 1, 2026)
PHASE1 Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC You Lu NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features Leiden University Medical Center NA RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer University Hospital, Linkoeping NA RECRUITING
(May 1, 2026)
PHASE2 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients Yonsei University NA COMPLETED
(May 1, 2026)
PHASE2 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE2 A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer University of Chicago NA RECRUITING
(May 1, 2026)
PHASE2 DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Day One Biopharmaceuticals, Inc. NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors AbbVie NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Study of Novel Treatment Combinations in Patients With Lung Cancer Gilead Sciences NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer University of Manitoba NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Dizal Pharmaceuticals NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer Semmelweis University NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy Yale University NA RECRUITING
(May 1, 2026)
PHASE1 Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma Melissa Lumish NA SUSPENDED
(May 1, 2026)
PHASE2 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) BicycleTx Limited NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Regeneron Pharmaceuticals NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer University of Michigan Rogel Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study Australasian Gastro-Intestinal Trials Group NA RECRUITING
(May 1, 2026)
PHASE2 ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC Filipa Lynce, MD NA TERMINATED
(May 1, 2026)
PHASE1 A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) Children's Oncology Group NA RECRUITING
(May 1, 2026)
PHASE3 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer AstraZeneca NA RECRUITING
(May 1, 2026)
PHASE3 Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. Fundación GECP NA RECRUITING
(May 1, 2026)
PHASE3 A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors Shanghai Hengrui Pharmaceutical Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors St. Jude Children's Research Hospital NA RECRUITING
(May 1, 2026)
PHASE2 A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) GlaxoSmithKline NA RECRUITING
(May 1, 2026)
PHASE1 Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) Sun Yat-sen University NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer NEC Bio B.V NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer Intergroupe Francophone de Cancerologie Thoracique NA RECRUITING
(May 1, 2026)
PHASE2 Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) Virginia Commonwealth University NA RECRUITING
(May 1, 2026)
PHASE2 A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer University of Maryland, Baltimore NA RECRUITING
(May 1, 2026)
PHASE1 A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC Shanghai Henlius Biotech NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients Medical University of South Carolina NA RECRUITING
(May 1, 2026)
PHASE2 Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy Shanghai Junshi Bioscience Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE2 Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer Queen Mary University of London NA RECRUITING
(May 1, 2026)
PHASE2 Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Asan Medical Center NA NOT YET RECRUITING
(May 1, 2026)
PHASE3 BBO-11818 in Adult Subjects With KRAS Mutant Cancer TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) NA RECRUITING
(May 1, 2026)
PHASE1 A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer Memorial Sloan Kettering Cancer Center NA RECRUITING
(May 1, 2026)
PHASE2 INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma Tongji Hospital NA RECRUITING
(May 1, 2026)
PHASE3 A Study of SKB518 in Patients With Lung Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE2 A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies AbbVie NA RECRUITING
(May 1, 2026)
PHASE2 Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer National Cancer Institute (NCI) NA RECRUITING
(May 1, 2026)
PHASE3 Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) CureVac NA WITHDRAWN
(May 1, 2026)
PHASE1 DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI Tianjin Medical University Cancer Institute and Hospital NA RECRUITING
(May 1, 2026)
PHASE2 Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer University of Kansas Medical Center NA RECRUITING
(May 1, 2026)
PHASE2 Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) RenJi Hospital NA RECRUITING
(May 1, 2026)
PHASE2 SKB500 Combinations in Patients With Small Cell Lung Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE2 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC CSPC Megalith Biopharmaceutical Co.,Ltd. NA NOT YET RECRUITING
(May 1, 2026)
PHASE3 Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer RenJi Hospital NA RECRUITING
(May 1, 2026)
PHASE2 A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE2 PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer N.N. Alexandrov National Cancer Centre NA RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer Fudan University NA NOT YET RECRUITING
(May 1, 2026)
PHASE2 Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer Gustave Roussy, Cancer Campus, Grand Paris NA NOT YET RECRUITING
(May 1, 2026)
PHASE3 Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NA RECRUITING
(May 1, 2026)
PHASE2 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer Shanghai Henlius Biotech NA NOT YET RECRUITING
(May 1, 2026)
PHASE1 Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC Sun Yat-sen University NA NOT YET RECRUITING
(May 1, 2026)
PHASE2 Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. Shanghai Allink Biotherapeutics Co., Ltd. NA NOT YET RECRUITING
(May 1, 2026)
PHASE2 Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. Shanghai Pulmonary Hospital, Shanghai, China NA NOT YET RECRUITING
(May 1, 2026)
PHASE3 Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial M.D. Anderson Cancer Center NA NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Fujian Cancer Hospital NA NOT YET RECRUITING
(May 1, 2026)
PHASE3 Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma zhang yi NA NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer Akeso NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma Taipei Medical University Hospital NA RECRUITING
(May 1, 2026)
PHASE2 Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer Hunan Cancer Hospital NA NOT YET RECRUITING
(May 1, 2026)
PHASE2 SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） CSPC Megalith Biopharmaceutical Co.,Ltd. NA NOT YET RECRUITING
(May 1, 2026)
PHASE3 Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Sun Yat-sen University NA RECRUITING
(May 1, 2026)
PHASE2 Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Sun Yat-sen University NA RECRUITING
(May 1, 2026)
PHASE2 Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma St. Jude Children's Research Hospital NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis Institut Claudius Regaud NA COMPLETED
(Apr 1, 2026)
PHASE2 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Children's Oncology Group NA COMPLETED
(Apr 1, 2026)
PHASE3 Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer Danish Gynecological Cancer Group NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment UNICANCER NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer National Cancer Institute (NCI) NA COMPLETED
(Apr 1, 2026)
PHASE2 Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity University College, London NA COMPLETED
(Apr 1, 2026)
PHASE2 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Children's Oncology Group NA RECRUITING
(Apr 1, 2026)
PHASE3 A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers Massachusetts General Hospital NA COMPLETED
(Apr 1, 2026)
PHASE1 Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) Hoffmann-La Roche NA TERMINATED
(Apr 1, 2026)
PHASE1, PHASE2 Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer Albert Einstein College of Medicine NA COMPLETED
(Apr 1, 2026)
PHASE2 M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer ImmunityBio, Inc. NA TERMINATED
(Apr 1, 2026)
PHASE3 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix Grupo Español de Investigación en Cáncer de Ovario NA COMPLETED
(Apr 1, 2026)
PHASE3 Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery National Cancer Institute (NCI) NA SUSPENDED
(Apr 1, 2026)
PHASE2, PHASE3 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma ETOP IBCSG Partners Foundation NA COMPLETED
(Apr 1, 2026)
PHASE3 NADIM II: Neo-Adjuvant Immunotherapy Fundación GECP NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC Sun Yat-sen University NA RECRUITING
(Apr 1, 2026)
PHASE2 Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma BeiGene NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China Guangdong Association of Clinical Trials NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. National Taiwan University Hospital NA COMPLETED
(Apr 1, 2026)
PHASE2 ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma ETOP IBCSG Partners Foundation NA COMPLETED
(Apr 1, 2026)
PHASE2 A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Takeda NA COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Shanghai Children's Medical Center NA RECRUITING
(Apr 1, 2026)
PHASE3 A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc NA RECRUITING
(Apr 1, 2026)
PHASE1 Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Northwestern University NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer City of Hope Medical Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy Fundación GECP NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Maximilian Diehn NA RECRUITING
(Apr 1, 2026)
PHASE3 Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Dana-Farber Cancer Institute NA RECRUITING
(Apr 1, 2026)
PHASE2 Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) McGill University Health Centre/Research Institute of the McGill University Health Centre NA TERMINATED
(Apr 1, 2026)
PHASE2 Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China NA COMPLETED
(Apr 1, 2026)
PHASE2, PHASE3 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer Arcus Biosciences, Inc. NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment University Medical Center Groningen NA COMPLETED
(Apr 1, 2026)
PHASE1 MicroRNA Profiles in Triple Negative Breast Cancer University College Hospital, Ibadan NA RECRUITING
(Apr 1, 2026)
PHASE2 Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer CanariaBio Inc. NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Fundación GECP NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers University of Chicago NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer ARCAGY/ GINECO GROUP NA RECRUITING
(Apr 1, 2026)
PHASE2 A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy ImmuneOncia Therapeutics Inc. NA RECRUITING
(Apr 1, 2026)
PHASE1 Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients Assistance Publique - Hôpitaux de Paris NA RECRUITING
(Apr 1, 2026)
PHASE1 A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) Memorial Sloan Kettering Cancer Center NA RECRUITING
(Apr 1, 2026)
PHASE2 Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Jonsson Comprehensive Cancer Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 ATATcH Alternating Treatment Plans for Advanced Cancer Rutgers, The State University of New Jersey NA RECRUITING
(Apr 1, 2026)
PHASE2 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer Fundación GECP NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma Lantern Pharma Inc. NA RECRUITING
(Apr 1, 2026)
PHASE2 A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung Technische Universität Dresden NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer Memorial Sloan Kettering Cancer Center NA RECRUITING
(Apr 1, 2026)
PHASE2 Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC RayzeBio, Inc. NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax UNICANCER NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC University of Kansas Medical Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors Fundación GECP NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations AstraZeneca NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC Sichuan University NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy Debiopharm International SA NA TERMINATED
(Apr 1, 2026)
PHASE1 MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer Hirva Mamdani NA RECRUITING
(Apr 1, 2026)
PHASE2 Pembrolizumab in Locally Advanced Sinonasal Carcinoma Istituti Clinici Scientifici Maugeri SpA NA RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Sandoz NA COMPLETED
(Apr 1, 2026)
PHASE3 Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma National Cancer Institute (NCI) NA RECRUITING
(Apr 1, 2026)
PHASE3 LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer Dana-Farber Cancer Institute NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma Children's Oncology Group NA RECRUITING
(Apr 1, 2026)
PHASE2 Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA WITHDRAWN
(Apr 1, 2026)
PHASE1, PHASE2 Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes Canadian Cancer Trials Group NA RECRUITING
(Apr 1, 2026)
PHASE3 Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC Sichuan University NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy University of Texas Southwestern Medical Center NA RECRUITING
(Apr 1, 2026)
PHASE2 High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer Emory University NA RECRUITING
(Apr 1, 2026)
PHASE2 Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC Second Hospital of Shanxi Medical University NA RECRUITING
(Apr 1, 2026)
PHASE2 Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma Samsung Medical Center NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC Sichuan University NA WITHDRAWN
(Apr 1, 2026)
PHASE1 ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC ORIC Pharmaceuticals NA RECRUITING
(Apr 1, 2026)
PHASE1 Embryonal Tumor With Multilayered Rosettes University of California, San Francisco NA RECRUITING
(Apr 1, 2026)
PHASE2 Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer Montefiore Medical Center NA RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer Celltrion NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% Swiss Cancer Institute NA RECRUITING
(Apr 1, 2026)
PHASE2 A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors Verastem, Inc. NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer Shanghai Shengdi Pharmaceutical Co., Ltd NA RECRUITING
(Apr 1, 2026)
PHASE3 Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA RECRUITING
(Apr 1, 2026)
PHASE2 Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Intergroupe Francophone de Cancerologie Thoracique NA RECRUITING
(Apr 1, 2026)
PHASE2 Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Sun Yat-sen University NA RECRUITING
(Apr 1, 2026)
PHASE2 Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) Fundación GECP NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC Yang Hong NA RECRUITING
(Apr 1, 2026)
PHASE2 Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy Yonsei University NA RECRUITING
(Apr 1, 2026)
PHASE2 Window of Opportunity in Preserving Laryngeal Function Trial Matthew Spector NA RECRUITING
(Apr 1, 2026)
PHASE2 A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC Tianjin Medical University Cancer Institute and Hospital NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC Sichuan University NA RECRUITING
(Apr 1, 2026)
PHASE2 Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC ImmunityBio, Inc. NA WITHDRAWN
(Apr 1, 2026)
PHASE3 Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. Hebei Medical University Fourth Hospital NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer Shanghai Municipal Hospital of Traditional Chinese Medicine NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC Fudan University NA RECRUITING
(Apr 1, 2026)
PHASE3 Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Second Affiliated Hospital of Zunyi Medical University NA RECRUITING
(Apr 1, 2026)
PHASE2 Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC Sichuan Cancer Hospital and Research Institute NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer Anhui Provincial Cancer Hospital NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer Henan Cancer Hospital NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL Hackensack Meridian Health NA COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer City of Hope Medical Center NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer University of Chicago NA COMPLETED
(Mar 1, 2026)
PHASE2 PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer Centre Oscar Lambret NA COMPLETED
(Mar 1, 2026)
PHASE2 Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Virginia Commonwealth University NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer M.D. Anderson Cancer Center NA COMPLETED
(Mar 1, 2026)
PHASE2 A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Astellas Pharma Global Development, Inc. NA TERMINATED
(Mar 1, 2026)
PHASE1, PHASE2 9-ING-41 in Patients With Advanced Cancers Actuate Therapeutics Inc. NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer Centre Oscar Lambret NA TERMINATED
(Mar 1, 2026)
PHASE2 Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NRG Oncology NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Children's Oncology Group NA RECRUITING
(Mar 1, 2026)
PHASE2 Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) BeiGene NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy InSightec NA COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery CanariaBio Inc. NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer Georgetown University NA RECRUITING
(Mar 1, 2026)
PHASE2 A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours PharmaMatrix Holdings Ltd NA RECRUITING
(Mar 1, 2026)
PHASE1 A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer Hoffmann-La Roche NA TERMINATED
(Mar 1, 2026)
PHASE2 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors Akeso NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC Akeso NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients Shanghai Chest Hospital NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) Intergroupe Francophone de Cancerologie Thoracique NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer Akeso NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer Biocon Biologics UK Ltd NA TERMINATED
(Mar 1, 2026)
PHASE3 Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer University of Chicago NA TERMINATED
(Mar 1, 2026)
PHASE1 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma Nanjing Leads Biolabs Co.,Ltd NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC Xencor, Inc. NA TERMINATED
(Mar 1, 2026)
PHASE1, PHASE2 A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Amgen NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer Ohio State University Comprehensive Cancer Center NA RECRUITING
(Mar 1, 2026)
PHASE2 Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors AstraZeneca NA RECRUITING
(Mar 1, 2026)
PHASE2 A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma Rapa Therapeutics LLC NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer Sun Yat-sen University NA RECRUITING
(Mar 1, 2026)
PHASE2 LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer Universitaire Ziekenhuizen KU Leuven NA RECRUITING
(Mar 1, 2026)
PHASE2 Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran NA RECRUITING
(Mar 1, 2026)
PHASE2 A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer Shanghai JMT-Bio Inc. NA RECRUITING
(Mar 1, 2026)
PHASE3 Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC Tianjin Medical University Cancer Institute and Hospital NA RECRUITING
(Mar 1, 2026)
PHASE2 A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors Mabwell (Shanghai) Bioscience Co., Ltd. NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) Guangdong Provincial People's Hospital NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients Shanghai Pulmonary Hospital, Shanghai, China NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence University of Washington NA RECRUITING
(Mar 1, 2026)
PHASE2 Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma Peking University First Hospital NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer Yayi He NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer Yayi He NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 
